Aside

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aside

Property Description
Active ingredient Etoposide (VP-16)
Form Solution for injection, Oral capsules
Pharmacological class Antineoplastic agent, Cytotoxic drug
General purpose To limit the proliferation of malignant cells
Origin Semisynthetic derivative of podophyllotoxin

What Type of Medicine is Aside (Etoposide)?

Aside is the trade name for a medicine containing the active substance Etoposide, which is classified as an antineoplastic agent and a cytotoxic drug. This classification means its primary systemic function is to be toxic to, or to kill, cells, particularly those that are rapidly dividing, a characteristic of malignant growth. Etoposide is a semisynthetic derivative of podophyllotoxin, a naturally occurring compound derived from the Mayapple plant. This unique origin underscores its design as a highly modified molecule for targeted medical application. Etoposide phosphate, an inactive prodrug variant, is also utilized in some preparations, which the body must convert into the active Etoposide compound. Etoposide is included in the Model List of Essential Medicines.


Aside's Forms, Composition, and General Purpose

The medicine is supplied as a single-ingredient product in two main dosage forms for systemic delivery: a solution for injection and oral capsules. The injection form, intended for controlled intravenous administration, is formulated as an aqueous/alcoholic solution. As a cytotoxic agent, the general purpose of Etoposide is to intervene at the cellular level by preventing malignant cells from properly managing their DNA during replication. Etoposide achieves this by targeting and disrupting a critical enzyme called Topoisomerase II. This action is essential for the general aim of limiting the growth and spread of cell populations associated with disease.

Regulatory References

  1. WHO Essential Medicines List
  2. NIH Cancer Drug Information

What side effects are possible with Aside?

Possible Side Effects and Safety Information

Aside (Etoposide) is a cytotoxic agent, and its documented safety profile is organized by the frequency and the System-Organ Class (SOC) affected. The most significant and dose-limiting toxicity officially classified in regulatory documents is myelosuppression (bone marrow suppression), leading to very common events such as neutropenia, thrombocytopenia, and anaemia. Other very common adverse effects include alopecia (hair loss), nausea, and vomiting.


Official Frequency Classifications

Classification Examples of Documented Effects
Very Common (ge 1/10) Myelosuppression (all types), Nausea, Vomiting, Alopecia
Common (ge 1/100 to < 1/10) Mucositis, Secondary Acute Leukaemia, Peripheral Neuropathy
Rare (ge 1/10,000 to < 1/1,000) Anaphylactic Reactions, Pulmonary Fibrosis, Seizures

Serious Safety Considerations

The official label lists secondary acute leukaemia as a common long-term risk. Serious reactions also include severe, potentially fatal myelosuppression and anaphylactic reactions. Due to the high risk of blood-related effects, regulatory agencies mandate frequent hematologic monitoring to manage the dose-limiting toxicity. Administration safety notes indicate that the intravenous solution must be administered slowly to mitigate the risk of hypotension.

Population-specific safety considerations include the documented risk of embryo-fetal toxicity and the potential for infertility in both sexes. Patients with impaired renal function are also noted to be at an increased risk of toxicity due to altered drug clearance, as stated in official labeling.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Aside (Etoposide) overdose is defined by the exacerbation of its known cytotoxic effects. Overdosage is primarily documented to result in profound myelosuppression, which manifests as severe decreases in leukocytes and platelets, potentially leading to fatal infections or hemorrhage. Severe non-hematological manifestations include gastrointestinal toxicity (severe mucositis, nausea, and vomiting) and documented Central Nervous System (CNS) effects, such as somnolence.

Required Emergency Actions

In the event of suspected overexposure, it is mandated that patients seek immediate medical attention by contacting emergency services. This action is critical for any severe symptoms, including signs of a severe hypersensitivity reaction (e.g., hypotension or difficulty breathing) or if the patient collapses. Regulatory information confirms that no specific antidote is known for Etoposide overdose; consequently, management is strictly symptomatic and supportive.

Management and Monitoring

Procedural steps officially described for management include the consideration of gastric lavage immediately following acute oral overdose. Following overexposure, close monitoring of complete blood counts (CBCs) and renal/hepatic function is required due to the risk of severe toxicity. For patients with renal impairment, a dose reduction is required due to reduced drug clearance, making this population a critical factor in overdose evaluation.

Therapeutic Uses of Aside

What Aside Treats: Main Uses and Benefits

The medicine is recognized for use across core therapeutic domains. The application of Aside (Etoposide) is relevant in malignant conditions, including Small Cell Lung Cancer (SCLC), various Testicular Cancers, and certain types of refractory leukemias and lymphomas.

The medicine is commonly used across conditions characterized by periods of heightened symptoms, where its use helps address symptom clusters associated with the malignancy. This treatment approach is considered relevant to provide support that helps ease the overall symptom burden.

“The treatment approach is commonly used when symptoms become more noticeable and when short-term symptomatic assistance is needed to stabilize aggressive progression.”

Aside is also applicable in clinical settings that involve acute or disruptive symptom patterns, such as salvage therapy for relapsed or refractory disease, where it may assist with managing symptoms related to systemic imbalance.

The benefit for patients may assist with easing distress that may arise directly from the tumor mass, such as symptoms related to physical discomfort or those that interfere with daily functioning. The therapy supports general well-being during symptomatic periods.


Quick Fact: Relief for Tumor-Related Discomfort The medicine is relevant for easing symptoms related to physical discomfort and functional strain caused by tumor size or spread, contributing to improved comfort when symptoms intensify.

Eligibility and Restrictions for Use

Absolute Contraindications

Aside (Etoposide) is formally contraindicated and must not be used in specific populations. These include patients with a documented history of severe hypersensitivity to the drug or any component of the formulation. Use is strictly prohibited during pregnancy (classified as Pregnancy Category D, as it can cause fetal harm) and when the patient is breastfeeding/lactating. The medicine is also contraindicated in immunosuppressed patients receiving a yellow fever vaccine or other live vaccines.


Conditional and Restricted Use

Eligibility may be restricted based on existing conditions. Patients with pre-existing severe myelosuppression (very low neutrophil or platelet counts) are ineligible for administration unless the underlying malignancy is the cause. Conditional use is mandated for patients with impaired renal function (Creatinine Clearance 15 to 50 mL/min), which requires a regulatory dose reduction. Furthermore, the label requires both men and women of childbearing potential to use effective contraception during and for a specified time following treatment.


Age-Group Eligibility

The medicine's use is established for the adult and older adult populations. However, official regulatory documents state that safety and effectiveness have not been established for all adult indications (such as testicular cancer) in the pediatric population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Aside (Etoposide) interacts with several medicinal products and substances, resulting in officially documented changes to its systemic exposure or pharmacodynamic effects. These interactions are categorized based on their mechanism and outcome as noted in regulatory labeling.

Pharmacokinetic Interactions

Co-administration with potent CYP3A4 inducers, such as phenytoin or carbamazepine, increases Etoposide clearance, resulting in reduced systemic exposure (AUC). Conversely, potent inhibitors of the P-glycoprotein (P-gp) transporter, such as high-dose Ciclosporin, reduce Etoposide's total body clearance, leading to increased systemic exposure. Sequential administration of Cisplatin is also associated with reduced Etoposide clearance.

Pharmacodynamic Interactions

Concurrent use with other myelosuppressive agents results in an additive pharmacodynamic effect, increasing the risk of myelotoxicity. Co-administration with Warfarin may enhance the anticoagulant effect, leading to an officially documented increase in the International Normalized Ratio (INR).

Other Documented Interactions

The consumption of Grapefruit Juice and the herbal product St John's Wort are officially noted to alter Etoposide’s exposure. Co-administration with live vaccines is formally contraindicated in immunosuppressed patients. Additionally, Impaired Renal Function is cited as a patient-specific condition that results in reduced total body clearance.

Mechanism of Action

Interruption of DNA Replication by Topoisomerase II Inhibition

The primary action of Etoposide is to target and inhibit the enzyme DNA Topoisomerase II within the cell nucleus. The drug binds to and stabilizes the transient DNA-enzyme complex after the DNA strands are cleaved, which critically prevents the re-ligation of the DNA. This mechanistic domain results in the creation of double-strand DNA breaks (DSBs).

Activation of the Apoptosis Cascade and Cell Cycle Arrest

The accumulation of irreparable DSBs triggers the cell's natural DNA Damage Response and activates cell cycle checkpoints, particularly in the S and G2 phases. When the damage is assessed as overwhelming, this mechanistic cascade initiates the cell's self-destruction program, known as apoptosis. The resulting physiological effect is the induction of apoptosis and the cessation of proliferation in susceptible cells.

Constraints Due to Cell Cycle Specificity and Efflux

The drug's mechanism is fundamentally dependent on the target cell being in an active phase of division (S or G2), demonstrating a functional constraint against quiescent cells. Furthermore, this mechanism is constrained by cellular defense systems; for instance, the overexpression of P-glycoprotein efflux pumps can actively transport the Etoposide out of the cell, thereby compromising the drug's ability to achieve sufficient stabilization of the cleavage complex, leading to a reduction in intracellular Topoisomerase II inhibition.

Dosage and Administration Information

Administration Routes and Scheduling

Etoposide is delivered through two official routes: as a solution for intravenous (IV) infusion and as oral soft capsules. The therapy is administered in a cyclic pattern, typically involving consecutive daily dosing for a short period—usually 3 to 5 days—followed by a rest period of 3 to 4 weeks to allow for biological recovery before the next course begins. The total number of cycles administered is generally determined by the treatment plan.


Dosage Principles and Adjustments

The dose is not a standard fixed amount; rather, it is calculated based on the patient's Body Surface Area (m^2). For example, IV regimens range from 50 to 100 milligrams per square meter per day, depending on the specific combination protocol. The oral dose for the capsules is officially designated as approximately double the corresponding IV dose.

Specific high-level dose adjustments are required for certain populations. Patients with moderate renal impairment (creatinine clearance between 15 and 50 mL/min) must receive a 25% dose reduction. No initial dose adjustment is required for older adults based on age alone.


Procedural Requirements

IV administration requires careful handling, as the concentrate must be diluted immediately before use to a specific concentration, generally not exceeding 0.4 mg/mL. The solution must then be administered by slow intravenous infusion over a minimum of 30 to 60 minutes. For the oral route, capsules must be taken on an empty stomach, generally one hour before or two hours after a meal. All use must occur under the supervision of a physician experienced in cytotoxic therapy.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Aside (Etoposide)

Evidence for use in Small Cell Lung Cancer (SCLC)

The clinical research for Etoposide in Small Cell Lung Cancer (SCLC) primarily consists of large Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies evaluated the medicine as part of established combination regimens with other antineoplastic agents, focusing on adults with both early and advanced SCLC. Research monitored outcomes such as overall survival duration, progression-free survival (time before disease advancement), and objective tumor response rate (change in tumor size). Findings described patterns related to these measurements in the studied populations.

Evidence for use in Testicular Cancer

The evidence includes numerous global Cooperative Group Studies and RCTs with extended observation periods, often spanning five to ten years or longer. Etoposide was evaluated in adults and children with various stages of germ cell tumors. Research examined long-term outcomes such as overall survival rates and disease-free survival. Studies monitored these outcomes when Etoposide was incorporated into highly specific, established standard of care combination regimens.

Evidence in Relapsed or Refractory Leukemias and Lymphomas

For patients whose disease did not respond to or returned after prior treatments, Etoposide was studied in salvage combination regimens. This evidence often stems from smaller Phase II Single-arm Trials. The outcomes research examined focused on short-term markers like Complete Remission (CR) rates). Findings were sometimes mixed and based on relatively modest sample sizes and heterogeneous populations, reflecting the nature of refractory disease.

Research Limitations and Uncertainty

Key limitations across the evidence base include the fact that results often apply only to the populations studied and that the specific impact of Etoposide alone is difficult to isolate, as it was studied for its role in multi-drug protocols. Data for long-term effects beyond five years are not fully established for all populations, and comparative evidence is lacking in some specific salvage settings.

Frequently Asked Questions (FAQ)

Common questions about Aside (FAQ)

Q: How quickly should I expect to feel the effects of Aside?

A: Official documents describe how quickly the medicine reaches its highest level in the body, which typically ranges from a few minutes (IV infusion) to one or two hours (oral capsule). However, the information does not specify when an individual should expect to feel the effects or when clinical results would be apparent, as this depends on the specific treatment regimen being followed.

Q: Are there any common foods or drinks to avoid while taking Aside?

A: Official product information notes an interaction with Grapefruit Juice, which is described as altering the body's exposure to the medicine. Additionally, the oral capsules are directed to be taken on an empty stomach (one hour before a meal or two hours after).

Q: Can I take pain relievers like ibuprofen with Aside?

A: Regulatory documents include a general caution about concurrent use with other myelosuppressive agents. Myelosuppressive agents are medicines that can lower blood cell counts, and combining them with Aside is noted to result in an additive pharmacodynamic effect, which increases the risk of myelotoxicity.

Q: Does Aside interact with supplements like St. John's Wort?

A: Yes, official documentation specifically states that the herbal product St. John's Wort is noted to alter the medicine's systemic exposure (the amount of drug available in the body). This is due to its effect on the enzymes responsible for breaking down the medicine.

Q: Does Aside have special considerations for older adults (seniors)?

A: Official guidance indicates that use is established for the older adult population. Clinical studies have not shown unique problems specific to elderly patients, and no initial dose adjustment is required based on age alone.

Q: Are there special considerations for children or teenagers taking Aside?

A: The medicine's official label states that safety and effectiveness have not been established for all adult indications in the pediatric population. When Aside is indicated, the dose is calculated based on the child's Body Surface Area (m^2), which is a common practice for this type of medication.

Q: Can Aside affect sleep patterns?

A: Official documents do not commonly report insomnia or sleepiness as very frequent side effects. However, documented adverse effects such as fever, nausea, or other reactions may indirectly impact a person's ability to rest.

Q: What does the official documentation say about stopping Aside treatment?

A: The therapy is administered in a cyclic pattern that involves scheduled days of treatment followed by rest periods. The total duration is generally determined by the treatment plan and the results of therapeutic monitoring.

Q: What types of drug-drug interactions are listed for Aside?

A: Interactions are described in two main categories: those that affect the levels of the drug in the body (e.g., with certain enzyme inhibitors or inducers) and those that cause additive effects (e.g., increased risk of blood-related issues when combined with other myelosuppressive agents).

Q: What is the research evidence for Aside's use in children?

A: The medicine has been evaluated in children for specific conditions, but official documentation notes that effectiveness has not been established for all adult uses.

Q: Is it normal for Aside to cause a slight upset stomach?

A: Yes, nausea and vomiting (medical terms for upset stomach) are listed in official documents as very common gastrointestinal side effects, meaning they are listed as very commonly occurring adverse effects.

Q: Does taking Aside require any special monitoring or blood tests?

A: Official regulatory agencies mandate frequent hematologic monitoring, which involves conducting blood tests at regular intervals. This is required to check blood cell counts due to the potential for myelosuppression (bone marrow suppression).

Q: Does Aside affect fertility?

A: Official labeling documents the potential for infertility (inability to have children) in both men and women. Official guidance notes that effective contraception is required during treatment and for a specified time period afterward.

Q: Does Aside change the way other medications work?

A: Yes, official documents indicate that Aside can alter the systemic exposure or pharmacodynamic effects of other medicines. This means it can either change the level of a co-administered drug in the body (pharmacokinetics) or change its effect (pharmacodynamics), such as enhancing the effect of a blood thinner like Warfarin.

Q: What is the likelihood of experiencing a rare side effect from Aside?

A: Side effects that are classified as rare are formally defined as occurring in 1 out of every 1,000 to 10,000 people. This classification is the official measure used in regulatory documents to categorize the frequency of adverse events.

Q: Does Aside cause weight gain or weight loss?

A: The official adverse effects profile lists common gastrointestinal issues, including loss of appetite, which is sometimes associated with weight loss.

Q: Can Aside make you feel dizzy or lightheaded?

A: Dizziness and lightheadedness are documented adverse reactions. These effects are sometimes associated with a drop in blood pressure (hypotension) or low red blood cell counts (anaemia), which are other documented side effects.

Q: Can Aside affect my ability to drive or operate machinery?

A: Official labeling does not contain a specific warning against driving; however, documented adverse effects such as dizziness and fatigue could impair the ability to perform skilled tasks or operate machinery.

Q: Can Aside be used for long-term treatment?

A: The medicine is administered in defined cycles of treatment and the overall duration is determined by the specific regimen and the patient's response to therapy. The medicine is administered in defined cycles of treatment and is not an indefinite continuous therapy.

Q: Can people with kidney or liver issues use Aside?

A: Official product information notes that patients with moderate renal impairment (kidney issues) are required to receive a dose reduction. Specific guidance is also provided for dose adjustment related to various degrees of hepatic impairment (liver issues).

Q: Are there different strengths of the Aside tablet/capsule?

A: Yes, the medicine is supplied in various strengths. This includes different concentrations for the solution for injection and multiple strengths for the oral capsules, such as 50 mg.

Q: How long does Aside stay in your system after the last dose?

A: Official pharmacokinetic data describes the terminal elimination half-life, which is the time it takes for the drug concentration to drop by half. This period is documented as ranging from 4 to 11 hours in adults following intravenous administration.

Q: Does the time of day I take Aside matter?

A: For the oral capsule, the procedural requirement is that it be taken on an empty stomach—one hour before or two hours after a meal. The timing of administration for the oral capsule is based on this procedural requirement.

Q: What is the intended duration of effect for a single dose of Aside?

A: The official measure of how long the drug remains in the body and potentially active is described by the terminal elimination half-life, which ranges from 4 to 11 hours in adults.

Q: Is Aside known to cause skin rashes?

A: Yes, official documents report that rash, urticaria (hives), and pruritus (itching) have all been documented as adverse effects.

Q: Can Aside cause issues with vision?

A: Official documentation notes that adverse effects involving sight have been reported. These include blurred vision and in rare instances, temporary loss of sight or blindness.

How should Aside be stored and disposed of?

How to Store and Dispose of Etoposide (Aside)

The official storage and disposal guidelines for Etoposide (Aside) are governed by regulatory requirements due to its classification as a cytotoxic agent.

Storage Requirements

  • Temperature and Protection: Store unopened vials and oral capsules at or below 25 C. The medicine must not be frozen. Unopened vials of the solution for injection must be protected from light.
  • Container and Integrity: Oral capsules must be kept in their original package. Blisters showing evidence of leakage must not be opened.
  • Child Safety: The medicine must be stored out of the sight and reach of children.

Handling and Disposal

Special caution and the use of gloves are required when handling Etoposide. Any unused product or waste material must be disposed of in accordance with local regulations for cytotoxic/hazardous waste, and it must not be thrown in household trash or flushed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aside found in:

A-Z Index: